Interview with professor Roger Hajjar (PT1) | PLN US Foundation

20 Visioni

Grazie! Condividilo con i tuoi amici!

Non hai gradito questo video. Grazie per il feedback!

Published Jul 4, 2025

Who is Roger J. Hajjar?

Dr. Roger J. Hajjar is an internationally recognized leader in cardiology and cardiovascular gene therapy, best known for his groundbreaking research on genetic heart diseases, including PLN-related cardiomyopathies like the PLN-R14del mutation. He is professor of Medicine and former Director of the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai.

Next to that, he is a pioneer in gene-based therapies for heart failure and founder of Celladon Corporation, one of the first bio-tech companies focused on gene therapy for cardiovascular disease. He has written hundreds of peer-reviewed scientific articles in the field of cardiology and heart failure.

What is his connection to PLN-R14del?

Dr. Hajjar is actively involved in global efforts to understand and treat inherited arrhythmogenic cardiomyopathies, including PLN-R14del. His expertise in gene transfer technology and heart function plays a vital role in the quest for a safe and effective therapy for PLN carriers.

He is a leading scientific partner in the GEREMY consortium, which brings together top institutions to develop a curative gene therapy for PLN and related mutations.